Probing for a deeper understanding of rhabdomyosarcoma: Insights from complementary model systems

Nature Reviews Cancer

Volumn 15, Issue 7, 2015, Pages 426-439

  Kashi, Venkatesh P ^a   Hatley, Mark E ^b   Galindo, Rene L ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PAIRED BOX TRANSCRIPTION FACTOR; PAX3 PROTEIN, HUMAN; PROTEIN P21; RAS PROTEIN;

CANCER MODEL; CARCINOGENESIS; CELL DIFFERENTIATION; DNA MODIFICATION; EMBRYONAL RHABDOMYOSARCOMA; FRUIT FLY MODEL; GENETIC MODEL; GENOMICS; HUMAN; MOUSE MODEL; MUSCLE STEM CELL; MUSCULAR DYSTROPHY; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; ZEBRA FISH; ANIMAL; DISEASE MODEL; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY; STEM CELL;

ANIMALS; DISEASE MODELS, ANIMAL; FORKHEAD BOX PROTEIN O1; FORKHEAD TRANSCRIPTION FACTORS; HEDGEHOG PROTEINS; HUMANS; MUTATION; MYOBLASTS; PAIRED BOX TRANSCRIPTION FACTORS; PAX3 TRANSCRIPTION FACTOR; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; RHABDOMYOSARCOMA; STEM CELLS;

EID: 84933040183     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3961     Document Type: Review

References (157)

1. Sultan I., Qaddoumi I., Yaser S., Rodriguez-Galindo C. & Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J. Clin. Oncol. 27, 3391-3397 (2009
2. Goldblum J., Folpe A. & Weiss S. in Enzinger and Weiss's Soft Tissue Tumors (eds Goldblum J., Folpe A. & Weiss S.) 601-638 (Elsevier Saunders, 2014
3. Wexler L., Meyer W. & Helman L. in Principles and Practice of Pediatric Oncology (eds Pizzo P. & Poplack D.) 923-953 (Lippincott WIlliams & Wilkins, 2011
4. Barr F. G., Montgomery E. A., Nascimento A. F., & Parham D. M. in WHO Classification of Tumours of Soft Tissue and Bone (eds Fletcher C. D. M., Bridge J. A., Hogendoorn P. & Mertens F.) 123-135 (IARC, 2013
5. Parham D. M. & Barr F. G. in WHO Classification of Tumours of Soft Tissue and Bone (eds Fletcher C. D. M., Bridge J. A., Hogendoorn P. & Mertens F.) 130-132 (IARC, 2013
6. Montgomery E. A. & Barr F. G. in WHO Classification of Tumours of Soft Tissue and Bone (eds Fletcher C. D. M., Bridge J. A., Hogendoorn P. & Mertens F.) 132-133 (IARC, 2013
7. Nascimento A. F. & Barr F. G. in WHO Classification of Tumours of Soft Tissue and Bone (eds Fletcher C. D. M., Bridge J. A., Hogendoorn P. & Mertens F.) 134-135 (IARC, 2013
8. Mosquera J. M., et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer 52, 538-550 (2013
9. Agaram N. P., et al. Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis. Genes Chromosomes Cancer 53, 779-787 (2014
10. Kohsaka S., et al. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat. Genet. 46, 595-600 (2014
11. Shapiro D. N., Sublett J. E., Li B., Downing J. R. & Naeve C. W. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res. 53, 5108-5112 (1993
12. Galili N., et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat. Genet. 5, 230-235 (1993
13. Davis R. J., D'Cruz C. M., Lovell M. A., Biegel J. A. & Barr F. G. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 54, 2869-2872 (1994
14. Xia S. J., Pressey J. G. & Barr F. G. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol. Ther. 1, 97-104 (2002
15. Sumegi J., et al. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator (NCOA) family. Genes Chromosomes Cancer 49, 224-236 (2010
16. Wachtel M., et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res. 64, 5539-5545 (2004
17. Shern J. F., et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 4, 216-231 (2014
18. Sorensen P. H., et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J. Clin. Oncol. 20, 2672-2679 (2002
19. Williamson D., et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J. Clin. Oncol. 28, 2151-2158 (2010
20. Sokolowski E., Turina C. B., Kikuchi K., Langenau D. M. & Keller C. Proof of concept rare cancers in drug development: the case for rhabdomyosarcoma. Oncogene 33, 1877-1889 (2014
21. Hettmer S., et al. Rhabdomyosarcoma: current challenges and their implications for developing therapies. Cold Spring Harb. Perspect. Med. 4, a025650 (2014
22. Keller C. & Guttridge D. C. Mechanisms of impaired differentiation in rhabdomyosarcoma. FEBS J. 280, 4323-4334 (2013
23. Davicioni E., et al. Molecular classification of rhabdomyosarcoma - genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am. J. Pathol. 174, 550-564 (2009
24. Shukla N., et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin. Cancer Res. 18, 748-757 (2012
25. Chen X., et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 24, 710-724 (2013
26. Hinson A. R., et al. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Front. Oncol. 3, 183 (2013
27. Linardic C. M., Downie D. L., Qualman S., Bentley R. C. & Counter C. M. Genetic modeling of human rhabdomyosarcoma. Cancer Res. 65, 4490-4495 (2005
28. Olson E. N., Spizz G. & Tainsky M. A. The oncogenic forms of N ras or H ras prevent skeletal myoblast differentiation. Mol. Cell. Biol. 7, 2104-2111 (1987
29. Stratton M. R., Fisher C., Gusterson B. A. & Cooper C. S. Detection of point mutations in N ras and K ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res. 49, 6324-6327 (1989
30. Schaaf G., et al. Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene. Cancer Res. 70, 762-771 (2010
31. Martinelli S., et al. RAS signaling dysregulation in human embryonal rhabdomyosarcoma. Genes Chromosomes Cancer 48, 975-982 (2009
32. Paulson V., et al. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer 50, 397-408 (2011
33. Aoki Y., et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat. Genet. 37, 1038-1040 (2005
34. Kratz C. P., et al. Uniparental disomy at chromosome 11p15.5 followed by HRAS mutations in embryonal rhabdomyosarcoma: lessons from Costello syndrome. Hum. Mol. Genet. 16, 374-379 (2007
35. Kratz C. P., et al. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. Br. J. Cancer 12, 1392-1397 (2015
36. Hettmer S., et al. Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells. Proc. Natl Acad. Sci. USA 108, 20002-20007 (2011
37. Linardic C. M., et al. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res. 67, 6691-6699 (2007
38. Naini S., et al. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res. 68, 9583-9588 (2008
39. Williamson D., et al. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J. Clin. Oncol. 23, 880-888 (2005
40. Kelly K. M., Womer R. B., Sorensen P. H., Xiong Q. B. & Barr F. G. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J. Clin. Oncol. 15, 1831-1836 (1997
41. Skapek S. X., et al. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report. Pediatr. Blood Cancer 60, 1411-1417 (2013
42. Anderson M. J., Shelton G. D., Cavenee W. K. & Arden K. C. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc. Natl Acad. Sci. USA 98, 1589-1594 (2001
43. Lagutina I., Conway S. J., Sublett J. & Grosveld G. C. Pax3-FKHR knock in mice show developmental aberrations but do not develop tumors. Mol. Cell. Biol. 22, 7204-7216 (2002
44. Relaix F., et al. The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain of function phenotype with ligand-independent activation of Met signaling in vivo. Genes Dev. 17, 2950-2965 (2003
45. Barr F. G. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 20, 5736-5746 (2001
46. Keller C., et al. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev. 18, 2614-2626 (2004
47. Nishijo K., et al. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res. 69, 2902-2911 (2009
48. Abraham J., et al. Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Mol. Cancer Ther. 10, 697-707 (2011
49. Hosoyama T., et al. IL 4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcoma. Clin. Cancer Res. 17, 2757-2766 (2011
50. Kikuchi K., et al. Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma. PLoS Genet. 10, e1004107 (2014
51. Abraham J., et al. Lineage of origin in rhabdomyosarcoma informs pharmacological response. Genes Dev. 28, 1578-1591 (2014
52. Coffin C. M., Davis J. L. & Borinstein S. C. Syndrome-associated soft tissue tumours. Histopathology 64, 68-87 (2014
53. Estep A. L., Tidyman W. E., Teitell M. A., Cotter P. D. & Rauen K. A. HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am. J. Med. Genet. A 140A, 8-16 (2006
54. Johnson R. L., et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272, 1668-1671 (1996
55. Li F. P. & Fraumeni J. F. Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J. Natl Cancer Inst. 43, 1365-1373 (1969
56. Ognjanovic S., Olivier M., Bergemann T. L. & Hainaut P. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer 118, 1387-1396 (2012
57. Diller L., Sexsmith E., Gottlieb A., Li F. P. & Malkin D. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J. Clin. Invest. 95, 1606-1611 (1995
58. Jacks T., et al. Tumor spectrum analysis in p53 mutant mice. Curr. Biol. 4, 1-7 (1994
59. Taylor A. C., et al. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med. Pediatr. Oncol. 35, 96-103 (2000
60. Keleti J., Quezado M. M., Abaza M. M., Raffeld M. & Tsokos M. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am. J. Pathol. 149, 143-151 (1996
61. Fleischmann A., Jochum W., Eferl R., Witowsky J. & Wagner E. F. Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos protooncogene. Cancer Cell 4, 477-482 (2003
62. Nanni P., et al. Development of rhabdomyosarcoma in HER 2/neu transgenic p53 mutant mice. Cancer Res. 63, 2728-2732 (2003
63. McMahon A. P., Ingham P. W. & Tabin C. J. Developmental roles and clinical significance of hedgehog signaling. Curr. Top. Dev. Biol. 53, 1-114 (2003
64. Gorlin R. J. Nevoid basal cell carcinoma syndrome. Dermatol. Clin. 13, 113-125 (1995
65. Hahn H., et al. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat. Med. 4, 619-622 (1998
66. Bridge J. A., et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: an intergroup rhabdomyosarcoma study. Genes Chromosomes Cancer 27, 337-344 (2000
67. Ragazzini P., et al. Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma. Histol. Histopathol. 19, 401-411 (2004
68. Pressey J. G., Anderson J. R., Crossman D. K., Lynch J. C. & Barr F. G. Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group. Pediatr. Blood Cancer 57, 930-938 (2011
69. Zibat A., et al. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Oncogene 29, 6323-6330 (2010
70. Corcoran R. B. & Scott M. P. A mouse model for medulloblastoma and basal cell nevus syndrome. J. Neurooncol. 53, 307-318 (2001
71. Hahn H., et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J. Biol. Chem. 275, 28341-28344 (2000
72. Tostar U., et al. Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J. Pathol. 208, 17-25 (2006
73. Lee Y., et al. Loss of suppressor-of fused function promotes tumorigenesis. Oncogene 26, 6442-6447 (2007
74. Mao J., et al. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res. 66, 10171-10178 (2006
75. Hettmer S., et al. Mutations in Hedgehog pathway genes in fetal rhabdomyomas. J. Pathol. 231, 44-52 (2013
76. Niwa H., Yamamura K. & Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108, 193-199 (1991
77. Epstein J. A., Shapiro D. N., Cheng J., Lam P. Y. & Maas R. L. Pax3 modulates expression of the c Met receptor during limb muscle development. Proc. Natl Acad. Sci. USA 93, 4213-4218 (1996
78. Trusolino L. & Comoglio P. M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer 2, 289-300 (2002
79. Sharp R., et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat. Med. 8, 1276-1280 (2002
80. Tatsumi R., Anderson J. E., Nevoret C. J., Halevy O. & Allen R. E. HGF/SF is present in normal adult skeletal muscle and is capable of activating satellite cells. Dev. Biol. 194, 114-128 (1998
81. Meadors J. L., et al. Murine rhabdomyosarcoma is immunogenic and responsive to T cell-based immunotherapy. Pediatr. Blood Cancer 57, 921-929 (2011
82. Yu Y., et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six 1 as key metastatic regulators. Nat. Med. 10, 175-181 (2004
83. Carneiro A., et al. Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas. J. Clin. Pathol. 64, 689-694 (2011
84. Yu Y., Davicioni E., Triche T. J. & Merlino G. The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res. 66, 1982-1989 (2006
85. Yu Y., et al. Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene. PLoS ONE 5, e12710 (2010
86. Bolden J. E., Peart M. J. & Johnstone R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769-784 (2006
87. Rossbach H. C., Lacson A., Grana N. H. & Barbosa J. L. Duchenne muscular dystrophy and concomitant metastatic alveolar rhabdomyosarcoma. J. Pediatr. Hematol. Oncol. 21, 528-530 (1999
88. Jakab Z., Szegedi I., Balogh E., Kiss C. & Olah E. Duchenne muscular dystrophy-rhabdomyosarcoma, ichthyosis vulgaris/acute monoblastic leukemia: association of rare genetic disorders and childhood malignant diseases. Med. Pediatr. Oncol. 39, 66-68 (2002
89. Fanzani A., Monti E., Donato R. & Sorci G. Muscular dystrophies share pathogenetic mechanisms with muscle sarcomas. Trends Mol. Med. 19, 546-554 (2013
90. Chamberlain J. S., Metzger J., Reyes M., Townsend D. & Faulkner J. A. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 21, 2195-2204 (2007
91. Fernandez K., Serinagaoglu Y., Hammond S., Martin L. T. & Martin P. T. Mice lacking dystrophin or α sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts. Am. J. Pathol. 176, 416-434 (2010
92. Schmidt W. M., et al. DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies. PLoS Genet. 7, e1002042 (2011
93. Sher R. B., Cox G. A., Mills K. D. & Sundberg J. P. Rhabdomyosarcomas in aging A/J mice. PLoS ONE 6, e23498 (2011
94. Hosur V., et al. Dystrophin and dysferlin double mutant mice: a novel model for rhabdomyosarcoma. Cancer Genet. 205, 232-241 (2012
95. Wang Y., et al. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat. Genet. 46, 601-606 (2014
96. White R., Rose K. & Zon L. Zebrafish cancer: the state of the art and the path forward. Nat. Rev. Cancer 13, 624-636 (2013
97. Srinivas B. P., Woo J., Leong W. Y. & Roy S. A conserved molecular pathway mediates myoblast fusion in insects and vertebrates. Nat. Genet. 39, 781-786 (2007
98. Langenau D. M., et al. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev. 21, 1382-1395 (2007
99. Ignatius M. S., et al. In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. Cancer Cell 21, 680-693 (2012
100. Doyle B., et al. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J. Pathol. 222, 129-137 (2010
101. Gonzalez C. Drosophila melanogaster: a model and a tool to investigate malignancy and identify new therapeutics. Nat. Rev. Cancer 13, 172-183 (2013
102. Xue L., Li X. & Noll M. Multiple protein functions of paired in Drosophila development and their conservation in the Gooseberry and Pax3 homologs. Development 128, 395-405 (2001
103. Xue L. & Noll M. The functional conservation of proteins in evolutionary alleles and the dominant role of enhancers in evolution. EMBO J. 15, 3722-3731 (1996
104. Brand A. H. & Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118, 401-415 (1993
105. Galindo R. L., Allport J. A. & Olson E. N. A. Drosophila model of the rhabdomyosarcoma initiator PAX7-FKHR. Proc. Natl Acad. Sci. USA 103, 13439-13444 (2006
106. Avirneni-Vadlamudi U., et al. Drosophila and mammalian models uncover a role for the myoblast fusion gene TANC1 in rhabdomyosarcoma. J. Clin. Invest. 122, 403-407 (2012
107. Rau A., et al. rolling pebbles (rols) is required in Drosophila muscle precursors for recruitment of myoblasts for fusion. Development 128, 5061-5073 (2001
108. Menon S. D. & Chia W. Drosophila rolling pebbles: a multidomain protein required for myoblast fusion that recruits D Titin in response to the myoblast attractant Dumbfounded. Dev. Cell 1, 691-703 (2001
109. Chen E. H. & Olson E. N. Antisocial, an intracellular adaptor protein, is required for myoblast fusion in Drosophila. Dev. Cell 1, 705-715 (2001
110. Crose L. E., et al. Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. J. Clin. Invest. 124, 285-296 (2014
111. Tremblay A. M., et al. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. Cancer Cell 26, 273-287 (2014
112. Liu-Chittenden Y., et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26, 1300-1305 (2012
113. Zhou Z., et al. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides. FASEB J. 29, 724-732 (2015
114. Spunt S. L., et al. Aggressive surgery is unwarranted for biliary tract rhabdomyosarcoma. J. Pediatr. Surg. 35, 309-316 (2000
115. Heyn R., et al. Preservation of the bladder in patients with rhabdomyosarcoma. J. Clin. Oncol. 15, 69-75 (1997
116. Lisboa S., et al. Genetic diagnosis of alveolar rhabdomyosarcoma in the bone marrow of a patient without evidence of primary tumor. Pediatr. Blood Cancer 51, 554-557 (2008
117. Shinkoda Y., Nagatoshi Y., Fukano R., Nishiyama K. & Okamura J. Rhabdomyosarcoma masquerading as acute leukemia. Pediatr. Blood Cancer 52, 286-287 (2009
118. Srinivas U., et al. A case of rhabdomyosarcoma masquerading as acute leukemia at presentation: a case report. Indian J. Pathol. Microbiol. 50, 917-919 (2007
119. Storer N. Y., et al. Zebrafish rhabdomyosarcoma reflects the developmental stage of oncogene expression during myogenesis. Development 140, 3040-3050 (2013
120. Heerema-McKenney A., et al. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype. Am. J. Surg. Pathol. 32, 1513-1522 (2008
121. Rubin B. P., et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell 19, 177-191 (2011
122. Brown C. B., Engleka K. A., Wenning J., Min Lu M. & Epstein J. A. Identification of a hypaxial somite enhancer element regulating Pax3 expression in migrating myoblasts and characterization of hypaxial muscle Cre transgenic mice. Genesis 41, 202-209 (2005
123. Blum J. M., et al. Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells. Cell Rep. 5, 933-940 (2013
124. Hatley M. E., et al. A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. Cancer Cell 22, 536-546 (2012
125. Tang W., et al. White fat progenitor cells reside in the adipose vasculature. Science 322, 583-586 (2008
126. Lee K. Y., et al. Lessons on conditional gene targeting in mouse adipose tissue. Diabetes 62, 864-874 (2013
127. Rajurkar M., et al. Distinct cellular origin and genetic requirement of Hedgehog-Gli in postnatal rhabdomyosarcoma genesis. Oncogene 33, 5370-5378 (2014
128. Weigel B., et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr. Blood Cancer 61, 452-456 (2014
129. Huang F., et al. Differential mechanisms of acquired resistance to insulin-like growth factor i receptor antibody therapy or to a small-molecule inhibitor, BMS 754807, in a human rhabdomyosarcoma model. Cancer Res. 70, 7221-7231 (2010
130. Pappo A. S., et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J. Clin. Oncol. 17, 3487-3493 (1999
131. Geoerger B., et al. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur. J. Cancer 48, 253-262 (2012
132. Aslam M. I., et al. Dynamic and nuclear expression of PDGFRα and IGF 1R in alveolar rhabdomyosarcoma. Mol. Cancer Res. 11, 1303-1313 (2013
133. Horsley V., Jansen K. M., Mills S. T. & Pavlath G. K. IL 4 acts as a myoblast recruitment factor during mammalian muscle growth. Cell 113, 483-494 (2003
134. Thalhammer V., et al. PLK1 phosphorylates PAX3- FOXO1, the inhibition of which triggers regression of alveolar rhabdomyosarcoma. Cancer Res. 75, 98-110 (2015
135. Albacker C. E., et al. The histone methyltransferase SUV39H1 suppresses embryonal rhabdomyosarcoma formation in zebrafish. PLoS ONE 8, e64969 (2013
136. Le X., et al. A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development. Development 140, 2354-2364 (2013
137. Chen E. Y., et al. Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma. Proc. Natl Acad. Sci. USA 111, 5349-5354 (2014
138. Wang H., et al. IFN-β production by TLR4 stimulated innate immune cells is negatively regulated by GSK3 β. J. Immunol. 181, 6797-6802 (2008
139. Patel S. & Woodgett J. Glycogen synthase kinase 3 and cancer: good cop, bad cop?. Cancer Cell 14, 351-353 (2008
140. Kremer A., Louis J. V., Jaworski T. & Van Leuven F. GSK3 and Alzheimer's disease: facts and fiction. Front. Mol. Neurosci. 4, 17 (2011
141. Renshaw J., et al. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clin. Cancer Res. 19, 5940-5951 (2013
142. Graab U., Hahn H. & Fulda S. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma. Oncotarget 6, 8722-8735 (2015
143. Lagutina I. V., et al. Modeling of the human alveolar rhabdomyosarcoma Pax3-Foxo1 chromosome translocation in mouse myoblasts using CRISPR-Cas9 nuclease. PLoS Genet. 11, e1004951 (2015
144. Tentler J. J., et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338-350 (2012
145. Siolas D. & Hannon G. J. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 73, 5315-5319 (2013
146. Monsma D. J., et al. Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance. Pediatr. Blood Cancer 61, 1570-1577 (2014
147. Stebbing J., et al. Patient-derived xenografts for individualized care in advanced sarcoma. Cancer 120, 2006-2015 (2014
148. Collins F. S. & Varmus H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793-795 (2015
149. Abmayr S. M. & Pavlath G. K. Myoblast fusion: lessons from flies and mice. Development 139, 641-656 (2012
150. Bour B. A., Chakravarti M., West J. M. & Abmayr S. M. Drosophila SNS, a member of the immunoglobulin superfamily that is essential for myoblast fusion. Genes Dev. 14, 1498-1511 (2000
151. Strunkelnberg M., et al. rst and its paralogue kirre act redundantly during embryonic muscle development in Drosophila. Development 128, 4229-4239 (2001
152. Ruiz-Gomez M., Coutts N., Price A., Taylor M. V. & Bate M. Drosophila dumbfounded: a myoblast attractant essential for fusion. Cell 102, 189-198 (2000
153. Onel S., Bolke L. & Klambt C. The Drosophila ARF6-GEF Schizo controls commissure formation by regulating Slit. Development 131, 2587-2594 (2004
154. Hindi S. M., Tajrishi M. M. & Kumar A. Signaling mechanisms in mammalian myoblast fusion. Sci. Signal. 6, re2 (2013
155. Sohn R. L., et al. A role for nephrin, a renal protein, in vertebrate skeletal muscle cell fusion. Proc. Natl Acad. Sci. USA 106, 9274-9279 (2009
156. Millay D. P., et al. Myomaker is a membrane activator of myoblast fusion and muscle formation. Nature 499, 301-305 (2013
157. Millay D. P. & Olson E. N. Making muscle or mitochondria by selective splicing of PGC 1α. Cell. Metab. 17, 3-4 (2013